Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
11/05/202015:05Business WireAcceleron Reports First Quarter 2020 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
05/05/202016:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
05/05/202006:00Business WireAcceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020NASDAQ:XLRNAcceleron Pharma Inc
04/05/202006:00Business WireAcceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary A...NASDAQ:XLRNAcceleron Pharma Inc
30/04/202016:15Dow Jones NewsBristol Myers, Acceleron Pharma's Anemia Treatment Gets Nod From European RegulatorNASDAQ:XLRNAcceleron Pharma Inc
30/04/202015:16Business WireReblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia & Myelodys...NASDAQ:XLRNAcceleron Pharma Inc
16/04/202015:36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
16/04/202015:34Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
10/04/202016:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
08/04/202006:05Business WireAcceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
07/04/202015:05Business WireAcceleron Announces Retirement of Director Jean GeorgeNASDAQ:XLRNAcceleron Pharma Inc
06/04/202009:46Dow Jones NewsAcceleron, Bristol-Myers Shares Up After New FDA Nod for ReblozylNASDAQ:XLRNAcceleron Pharma Inc
03/04/202016:08Business WireU.S. Food & Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First & Only Erythroid Maturation Agent, t...NASDAQ:XLRNAcceleron Pharma Inc
26/03/202005:59Business WireNew England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult...NASDAQ:XLRNAcceleron Pharma Inc
25/03/202009:58Dow Jones NewsFDA Target Action Date Arrives For Bristol-Myers' OzanimodNASDAQ:XLRNAcceleron Pharma Inc
09/03/202015:05Business WireAcceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth DiseaseNASDAQ:XLRNAcceleron Pharma Inc
27/02/202015:29Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XLRNAcceleron Pharma Inc
27/02/202015:20Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
27/02/202015:05Business WireAcceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
26/02/202006:00Business WireAcceleron to Participate in Two Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
18/02/202006:00Business WireAcceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020NASDAQ:XLRNAcceleron Pharma Inc
14/02/202012:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
10/02/202017:02Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:XLRNAcceleron Pharma Inc
27/01/202015:01Business WireAcceleron Announces Sotatercept Achieved Primary & Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Pati...NASDAQ:XLRNAcceleron Pharma Inc
23/01/202015:15Business WireAcceleron Announces Change to Executive Management TeamNASDAQ:XLRNAcceleron Pharma Inc
09/01/202005:59Business WireNew England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST TrialNASDAQ:XLRNAcceleron Pharma Inc
06/01/202006:00Business WireAcceleron to Participate in the 38th Annual J.P. Morgan Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
30/12/201906:30Business WireAcceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration AgreementNASDAQ:XLRNAcceleron Pharma Inc
17/12/201917:20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
09/12/201915:30Business WireReblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of...NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN